Jessica Gasparello
Overview
Explore the profile of Jessica Gasparello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
581
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gasparello J, Verona M, Chilin A, Gambari R, Marzaro G
Int J Biol Macromol
. 2023 Sep;
253(Pt 5):127088.
PMID: 37774812
The emergence of different coronavirus-related diseases in the 2000's (SARS, MERS, and Covid-19) warrants the need of a complete understanding of the pathological, biological, and biochemical behavior of this class...
12.
Gambari R, Zuccato C, Cosenza L, Zurlo M, Gasparello J, Finotti A, et al.
Biology (Basel)
. 2023 Sep;
12(9).
PMID: 37759601
In this review article, we present the fascinating story of rapamycin (sirolimus), a drug able to induce γ-globin gene expression and increased production of fetal hemoglobin (HbF) in erythroid cells,...
13.
Gasparello J, Papi C, Zurlo M, Volpi S, Gambari R, Corradini R, et al.
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631335
One of the most appealing approaches for regulating gene expression, named the "microRNA therapeutic" method, is based on the regulation of the activity of microRNAs (miRNAs), the intracellular levels of...
14.
Gasparello J, Marzaro G, Papi C, Gentili V, Rizzo R, Zurlo M, et al.
Int J Mol Med
. 2023 Jul;
52(3).
PMID: 37477130
Since its spread at the beginning of 2020, the coronavirus disease 2019 (COVID‑19) pandemic represents one of the major health problems. Despite the approval, testing, and worldwide distribution of anti‑severe...
15.
Tupini C, Zurlo M, Gasparello J, Lodi I, Finotti A, Scattolin T, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242574
Combined treatments employing lower concentrations of different drugs are used and studied to develop new and more effective anticancer therapeutic approaches. The combination therapy could be of great interest in...
16.
Papi C, Gasparello J, Zurlo M, Cosenza L, Gambari R, Finotti A
Noncoding RNA
. 2023 Apr;
9(2).
PMID: 37104011
(1) Background: MicroRNAs are involved in the expression of the gene encoding the chloride channel CFTR (Cystic Fibrosis Transmembrane Conductance Regulator); the objective of this short report is to study...
17.
Zurlo M, Gasparello J, Cosenza L, Breveglieri G, Papi C, Zuccato C, et al.
Genes (Basel)
. 2023 Mar;
14(3).
PMID: 36980829
One of the most relevant pathophysiological hallmarks of β-thalassemia is the accumulation of toxic α-globin chains inside erythroid cells, which is responsible for their premature death (hemolysis). In this context,...
18.
Zurlo M, Nicoli F, Proietto D, Dallan B, Zuccato C, Cosenza L, et al.
J Cell Mol Med
. 2023 Jan;
27(3):353-364.
PMID: 36625233
Inhibitors of the mammalian target of rapamycin (mTOR) have been proposed to improve vaccine responses, especially in the elderly. Accordingly, testing mTOR inhibitors (such as Sirolimus) and other geroprotective drugs...
19.
Zuccato C, Cosenza L, Zurlo M, Breveglieri G, Bianchi N, Lampronti I, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36614221
The human homologue of mouse Ly-1 antibody reactive clone protein (LYAR) is a putative novel regulator of γ-globin gene transcription. The LYAR DNA-binding motif (5′-GGTTAT-3′) is located within the 5′-UTR...
20.
Gasparello J, Papi C, Zurlo M, Gambari L, Manicardi A, Rozzi A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612125
Liquid biopsy has dramatically changed cancer management in the last decade; however, despite the huge number of miRNA signatures available for diagnostic or prognostic purposes, it is still unclear if...